Our work can guide human trials in which the efficacy of IRAK4 inhibitors available for human use or dietary interventions that increase TMA bioavailability can be evaluated in the context of obesity and IR. Here, IRAK4 is linked to obesity due to melanocortin 4 receptor deficiency.